Patients who received Johnson & Johnson's drug-coated stent Cypher have lower rates of blood clot recurrence compared with those who received bare-metal devices, while Boston Scientific Corp.'s Taxus stent was found to be as safe after two years for use in sicker heart patients as for use in those who were healthier, according to studies presented at a conference in Washington, D.C. "[Drug-eluting] stent safety is a hot-button topic, and the big question we see coming out of the meeting will be whether utilization picks back up," a market analyst said.

Full Story:

Related Summaries